Home GPCR & G Protein LPA Receptor

LPA Receptor

Isoform-selective Products

Signaling Pathway

LPA Receptor Signaling Pathway

LPA Receptor Products

  • All (9)
  • LPA Receptor Antagonists (8)
  • LPA Receptor Agonist (1)
  • New LPA Receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1315 Ki16425 Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM in RH7777 cell lines, respectively, shows no activity at LPA4, LPA5, LPA6.
J Ovarian Res, 2023, 16(1):137
J Ovarian Res, 2023, 16(1):137
Cell Rep, 2022, 39(12):110994
S2906 Ki16198 Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6.
Neurosci Bull, 2016, 32(5):445-54
S8345 ONO-7300243 ONO-7300243 is a novel, potent LPA1(Lysophosphatidic Acid Receptor) antagonist with an IC50 of 160 nM.
Eur J Pharmacol, 2020, 868:172886
S6633 AM 095 AM095 is an antagonist of the LPA type 1 receptor with IC50 values of 0.98 and 0.73 μM for recombinant human and mouse LPA1, respectively.
Gastroenterology, 2022, 162(4):1210-1225
E1036New BMS-986278 BMS-986278 is a potent and orally active antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986278 exhibits Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively, and is widely used in the research of pulmonary fibrotic diseases.
S3534 AM966 AM966 is a high affinity, selective, oral Lysophosphatidic acid receptor 1 (LPA1) antagonist, which can inhibit LPA-stimulated intracellular calcium release (IC50=17 nM, by Ca flux assay).
S3572 BMS-986020 BMS-986020 (AM152, AP-3152 free acid) is a potent and selective antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986020 inhibits bile acid and phospholipid transporters with IC50 of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).
E1941New ACT-1016-0707 ACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.
E2992 Oleoyl-L-alpha-lysophosphatidic acid sodium salt Oleoyl-L-alpha-lysophosphatidic acid sodium salt is an essential metabolite for membrane biosynthesis. LPA interacts with the G protein-coupled receptors (GPCRs), called the LPA receptor and mediates signaling. It acts as a endogenous agonist for LPA1 and LPA2 receptors.
S1315 Ki16425 Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM in RH7777 cell lines, respectively, shows no activity at LPA4, LPA5, LPA6.
J Ovarian Res, 2023, 16(1):137
J Ovarian Res, 2023, 16(1):137
Cell Rep, 2022, 39(12):110994
S2906 Ki16198 Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6.
Neurosci Bull, 2016, 32(5):445-54
S8345 ONO-7300243 ONO-7300243 is a novel, potent LPA1(Lysophosphatidic Acid Receptor) antagonist with an IC50 of 160 nM.
Eur J Pharmacol, 2020, 868:172886
S6633 AM 095 AM095 is an antagonist of the LPA type 1 receptor with IC50 values of 0.98 and 0.73 μM for recombinant human and mouse LPA1, respectively.
Gastroenterology, 2022, 162(4):1210-1225
E1036New BMS-986278 BMS-986278 is a potent and orally active antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986278 exhibits Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively, and is widely used in the research of pulmonary fibrotic diseases.
S3534 AM966 AM966 is a high affinity, selective, oral Lysophosphatidic acid receptor 1 (LPA1) antagonist, which can inhibit LPA-stimulated intracellular calcium release (IC50=17 nM, by Ca flux assay).
S3572 BMS-986020 BMS-986020 (AM152, AP-3152 free acid) is a potent and selective antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986020 inhibits bile acid and phospholipid transporters with IC50 of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).
E1941New ACT-1016-0707 ACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.
E2992 Oleoyl-L-alpha-lysophosphatidic acid sodium salt Oleoyl-L-alpha-lysophosphatidic acid sodium salt is an essential metabolite for membrane biosynthesis. LPA interacts with the G protein-coupled receptors (GPCRs), called the LPA receptor and mediates signaling. It acts as a endogenous agonist for LPA1 and LPA2 receptors.
E1036New BMS-986278 BMS-986278 is a potent and orally active antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986278 exhibits Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively, and is widely used in the research of pulmonary fibrotic diseases.
E1941New ACT-1016-0707 ACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases.

Choose Selective LPA Receptor Inhibitors

Tags: LPA Receptor inhibitor|LPA Receptor agonist|LPA Receptor activator|LPA Receptor inducer|LPA Receptor antagonist|LPA Receptor signaling pathway|LPA Receptor assay kit